"In addition, using the short epitope peptides based on precise motifs also will improve the effectiveness of making monoclonal or polyclonal antibodies for the development of therapeutic biologics or detection agents. Obviously, whether these goals can be achieved by using short epitope peptides or multi-epitope peptides to develop detection antigen, vaccines or therapeutic biologics, will first depend on the identification of a complete set of linear B-cell epitopes and their precise motifs in a target antigen protein.
"A large amount ohf research data demonstrated that cervical cancer, which ranks 2nd globally in the death rates of female cancers, is 90% related to persisted infection at the epidermal of gynecological tract with high-risk (HR-) HPV subtypes, such as HPV 16, 18, 31 and 45 (1). Currently, two pharmaceutical companies (Merck in the U.S. and
"Because most women infected by HPV can usually automatically eliminate the infected HPV, and only those, who are continuously infected by HPV, will resulted in cervical cancer, it becomes very important to develop inexpensive and convenient serum detection for HPV infection. Obviously, screening with such detection kits has great significance because such screening can determine who are the objects of vaccination with specific preventative or therapeutic HPV vaccines and what types of specific HPV vaccines should be used. Because of the limitations of early methodologies for epitope identification, it is almost impossible to identify a complete set of linear epitopes (particularly their minimal motifs) on a target protein. Identification of such epitopes or their minimal motifs can improve the detection accuracy, avoiding cross reactions with one or some of thousands of antibodies against unknown antigens present in normal human serum. Currently, no sensitive specific serological detection method for HPV infection has been established, even though in the early time, HPV-infected serum was used to identify specific markers for serological detection of HPV infections (2-5).
"HPV 58 is one of the high-risk (HR)-HPVs after HPV 16 and 18 (6). Recent research also demonstrated that high positive detection rates for HPV 58 have been shown in cervical cancer patients in many areas of
In addition to obtaining background information on this patent application, NewsRx editors also obtained the inventors' summary information for this patent application: "In view of the stated facts that the HR-HPV 58 is highly epidemic in many areas of
Most Popular Stories
- Twitter Names Woman to Board
- Obamacare Doing Just Fine, Ky. Governor Says
- Rand Paul Signs up for Obamacare
- Thalia Gets Star on Hollywood Walk of Fame
- How to Arm Yourself Against CryptoLocker Virus
- Hispanic Employment Improves in November
- World Cup Draws: Coaches, Players Offer Insights
- Trapped Florida Whales Head for Deeper Waters
- Aspen Contracting Adding 300 Jobs
- Dow Jumps 200 Points on Jobs Data